Brentuximab vedotin with chemotherapy for patients with previously untreated Stage III/IV classical hodgkin lymphoma: 5-Year update of the ECHELON-1 study
Authors
Ramchandren, R.Dlugosz-Danecka, M.
Connors, J. M.
Radford, John A
Illes, A.
Picardi, M.
Lech-Maranda, E.
Feldman, T.
Smolewski, P.
Savage, K. J.
Bartlett, N. L.
Walewski, J.
Zinzani, P. L.
Hutchings, M.
Munoz, J.
Kim, W. S.
Advani, R.
Ansell, S. M.
Gallamini, A.
Alekseev, S.
Lee, H. J.
Liu, R.
Little, M.
Fenton, K.
Fanale, M.
Straus, D. J.
Affiliation
The University of Tennessee Graduate School of Medicine, Knoxville, Tennessee, USAIssue Date
2021